APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Group A and C Meningococcal Polysaccharide Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Group A and C Meningococcal Polysaccharide Vaccine Market Analysis and Forecast 2026-2032

27 December 2025191 pages

Choose your research edition.

Industry ResearchGroup A and C Meningococcal Polysaccharide Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Group A and C Meningococcal Polysaccharide Vaccine Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Group A and C Meningococcal Polysaccharide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Group A and C Meningococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Group A and C Meningococcal Polysaccharide Vaccine Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Group A and C Meningococcal Polysaccharide Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Group A and C Meningococcal Polysaccharide Vaccine include Pfizer, Sanofi Pasteur, AIM Bio, Chengda Biotechnology, GlaxoSmithKline, Cansino Biologics, Sinovac, Lanzhou Institute of Biological Products and Royal (Wuxi) Bio-Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Group A and C Meningococcal Polysaccharide Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Group A and C Meningococcal Polysaccharide Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Group A and C Meningococcal Polysaccharide Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Group A and C Meningococcal Polysaccharide Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Group A and C Meningococcal Polysaccharide Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Group A and C Meningococcal Polysaccharide Vaccine sales, projected growth trends, production technology, application and end-user industry.

Group A and C Meningococcal Polysaccharide Vaccine Segment by Company

Pfizer

Sanofi Pasteur

AIM Bio

Chengda Biotechnology

GlaxoSmithKline

Cansino Biologics

Sinovac

Lanzhou Institute of Biological Products

Royal (Wuxi) Bio-Pharmaceutical

Merck & Co.

Toyouvax

Walvax

Zhifei Biological

Group A and C Meningococcal Polysaccharide Vaccine Segment by Type

Polysaccharide-protein Conjugate Vaccine

Polysaccharide Vaccine

Group A and C Meningococcal Polysaccharide Vaccine Segment by Application

Hospital

Centers for Disease Control and Prevention

Others

Group A and C Meningococcal Polysaccharide Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Group A and C Meningococcal Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Group A and C Meningococcal Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Group A and C Meningococcal Polysaccharide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Group A and C Meningococcal Polysaccharide Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Group A and C Meningococcal Polysaccharide Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Group A and C Meningococcal Polysaccharide Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Group A and C Meningococcal Polysaccharide Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Polysaccharide-protein Conjugate Vaccine Major Manufacturers Table 3. Polysaccharide Vaccine Major Manufacturers Table 4. Global Group A and C Meningococcal Polysaccharide Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Manufacturers Table 6. Centers for Disease Control and Prevention Major Manufacturers Table 7. Others Major Manufacturers Table 8. Group A and C Meningococcal Polysaccharide Vaccine Industry Trends Table 9. Group A and C Meningococcal Polysaccharide Vaccine Industry Drivers Table 10. Group A and C Meningococcal Polysaccharide Vaccine Industry Opportunities and Challenges Table 11. Group A and C Meningococcal Polysaccharide Vaccine Industry Restraints Table 12. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2021-2026) Table 16. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2027-2032) Table 17. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (Units) Table 18. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2021-2026) & (Units) Table 19. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2027-2032) & (Units) Table 20. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2021-2026) Table 21. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2027-2032) Table 22. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Manufacturers (2021-2026) Table 26. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Group A and C Meningococcal Polysaccharide Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Group A and C Meningococcal Polysaccharide Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Group A and C Meningococcal Polysaccharide Vaccine Manufacturers, Product Type & Application Table 30. Global Group A and C Meningococcal Polysaccharide Vaccine Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Group A and C Meningococcal Polysaccharide Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2026) Table 37. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2027-2032) Table 38. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type 2021 VS 2025 VS 2032 (Units) Table 39. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (Units) Table 40. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (Units) Table 41. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2026) Table 42. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2027-2032) Table 43. Global Group A and C Meningococcal Polysaccharide Vaccine Price by Type (2021-2026) & (US$/Unit) Table 44. Global Group A and C Meningococcal Polysaccharide Vaccine Price by Type (2027-2032) & (US$/Unit) Table 45. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2026) Table 49. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2027-2032) Table 50. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application 2021 VS 2025 VS 2032 (Units) Table 51. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (Units) Table 52. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (Units) Table 53. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2026) Table 54. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2027-2032) Table 55. Global Group A and C Meningococcal Polysaccharide Vaccine Price by Application (2021-2026) & (US$/Unit) Table 56. Global Group A and C Meningococcal Polysaccharide Vaccine Price by Application (2027-2032) & (US$/Unit) Table 57. Pfizer Company Information Table 58. Pfizer Business Overview Table 59. Pfizer Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Pfizer Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 61. Pfizer Recent Development Table 62. Sanofi Pasteur Company Information Table 63. Sanofi Pasteur Business Overview Table 64. Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 66. Sanofi Pasteur Recent Development Table 67. AIM Bio Company Information Table 68. AIM Bio Business Overview Table 69. AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 71. AIM Bio Recent Development Table 72. Chengda Biotechnology Company Information Table 73. Chengda Biotechnology Business Overview Table 74. Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 76. Chengda Biotechnology Recent Development Table 77. GlaxoSmithKline Company Information Table 78. GlaxoSmithKline Business Overview Table 79. GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 81. GlaxoSmithKline Recent Development Table 82. Cansino Biologics Company Information Table 83. Cansino Biologics Business Overview Table 84. Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 86. Cansino Biologics Recent Development Table 87. Sinovac Company Information Table 88. Sinovac Business Overview Table 89. Sinovac Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Sinovac Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 91. Sinovac Recent Development Table 92. Lanzhou Institute of Biological Products Company Information Table 93. Lanzhou Institute of Biological Products Business Overview Table 94. Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 96. Lanzhou Institute of Biological Products Recent Development Table 97. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 98. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 99. Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 101. Royal (Wuxi) Bio-Pharmaceutical Recent Development Table 102. Merck & Co. Company Information Table 103. Merck & Co. Business Overview Table 104. Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 106. Merck & Co. Recent Development Table 107. Toyouvax Company Information Table 108. Toyouvax Business Overview Table 109. Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 111. Toyouvax Recent Development Table 112. Walvax Company Information Table 113. Walvax Business Overview Table 114. Walvax Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Walvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 116. Walvax Recent Development Table 117. Zhifei Biological Company Information Table 118. Zhifei Biological Business Overview Table 119. Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 121. Zhifei Biological Recent Development Table 122. North America Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 123. North America Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 124. North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (Units) Table 125. North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (Units) Table 126. North America Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 127. North America Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 128. North America Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 129. North America Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 130. North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (Units) Table 131. North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (Units) Table 132. North America Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 133. North America Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 134. North America Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. North America Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 136. North America Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 137. North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 138. North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (Units) Table 139. North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (Units) Table 140. North America Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 141. North America Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 142. United States Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 143. Canada Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 144. Mexico Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 145. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 146. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 147. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (Units) Table 148. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (Units) Table 149. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 150. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 151. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 152. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 153. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (Units) Table 154. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (Units) Table 155. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 156. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 157. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 158. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 159. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 160. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 161. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (Units) Table 162. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (Units) Table 163. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 164. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 165. Germany Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 166. France Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 167. U.K. Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 168. Italy Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 169. Russia Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 170. Spain Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 171. Netherlands Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 172. Switzerland Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 173. Sweden Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 174. Poland Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 175. China Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 176. China Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 177. China Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (Units) Table 178. China Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (Units) Table 179. China Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 180. China Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 181. China Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 182. China Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 183. China Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (Units) Table 184. China Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (Units) Table 185. China Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 186. China Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 187. Asia Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 188. Asia Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 189. Asia Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (Units) Table 190. Asia Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (Units) Table 191. Asia Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 192. Asia Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 193. Asia Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 194. Asia Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 195. Asia Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (Units) Table 196. Asia Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (Units) Table 197. Asia Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 198. Asia Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 199. Asia Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 200. Asia Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 201. Asia Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 202. Asia Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 203. Asia Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (Units) Table 204. Asia Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (Units) Table 205. Asia Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 206. Asia Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 207. Japan Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 208. South Korea Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 209. India Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 210. Australia Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 211. Taiwan Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 212. Southeast Asia Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 213. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 214. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 215. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (Units) Table 216. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (Units) Table 217. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 218. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 219. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 220. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 221. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (Units) Table 222. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (Units) Table 223. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 224. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 225. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 226. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 227. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 228. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 229. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (Units) Table 230. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (Units) Table 231. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 232. SAMEA Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 233. Brazil Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 234. Argentina Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 235. Chile Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 236. Colombia Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 237. Peru Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 238. Saudi Arabia Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 239. Israel Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 240. UAE Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 241. Turkey Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 242. Iran Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 243. Egypt Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 244. Key Raw Materials Table 245. Raw Materials Key Suppliers Table 246. Group A and C Meningococcal Polysaccharide Vaccine Distributors List Table 247. Group A and C Meningococcal Polysaccharide Vaccine Customers List Table 248. Research Programs/Design for This Report Table 249. Authors List of This Report Table 250. Secondary Sources Table 251. Primary Sources List of Figures Figure 1. Group A and C Meningococcal Polysaccharide Vaccine Image Figure 2. Global Group A and C Meningococcal Polysaccharide Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Group A and C Meningococcal Polysaccharide Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Polysaccharide-protein Conjugate Vaccine Image Figure 5. Polysaccharide Vaccine Image Figure 6. Global Group A and C Meningococcal Polysaccharide Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Group A and C Meningococcal Polysaccharide Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Centers for Disease Control and Prevention Image Figure 10. Others Image Figure 11. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Figure 13. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2021-2032) Figure 16. Global Group A and C Meningococcal Polysaccharide Vaccine Sales (2021-2032) & (Units) Figure 17. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 18. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Group A and C Meningococcal Polysaccharide Vaccine Sales YoY (2021-2032) & (Units) Figure 20. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales YoY (2021-2032) & (Units) Figure 21. China Group A and C Meningococcal Polysaccharide Vaccine Sales YoY (2021-2032) & (Units) Figure 22. Asia (Excluding China) Group A and C Meningococcal Polysaccharide Vaccine Sales YoY (2021-2032) & (Units) Figure 23. South America, Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Sales YoY (2021-2032) & (Units) Figure 24. Global Group A and C Meningococcal Polysaccharide Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Group A and C Meningococcal Polysaccharide Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2032) Figure 30. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021 VS 2025 VS 2032) & (Units) Figure 31. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2032) Figure 33. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2032) Figure 36. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021 VS 2025 VS 2032) & (Units) Figure 37. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2032) Figure 39. North America Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Type (2021-2032) Figure 40. North America Group A and C Meningococcal Polysaccharide Vaccine Sales Share by Type (2021-2032) Figure 41. North America Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Application (2021-2032) Figure 42. North America Group A and C Meningococcal Polysaccharide Vaccine Sales Share by Application (2021-2032) Figure 43. North America Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Country (2021-2032) Figure 44. North America Group A and C Meningococcal Polysaccharide Vaccine Sales Share by Country (2021-2032) Figure 45. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Type (2021-2032) Figure 46. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Share by Type (2021-2032) Figure 47. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Application (2021-2032) Figure 48. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Share by Application (2021-2032) Figure 49. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Country (2021-2032) Figure 50. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Share by Country (2021-2032) Figure 51. China Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Type (2021-2032) Figure 52. China Group A and C Meningococcal Polysaccharide Vaccine Sales Share by Type (2021-2032) Figure 53. China Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Application (2021-2032) Figure 54. China Group A and C Meningococcal Polysaccharide Vaccine Sales Share by Application (2021-2032) Figure 55. Asia Group A and C Meningococcal Polysaccharide Vaccine Revenue

Scope & coverage.

Types
  • Polysaccharide-protein Conjugate Vaccine
  • Polysaccharide Vaccine
Applications
  • Hospital
  • Centers for Disease Control and Prevention
  • Others
Companies covered
  • Pfizer
  • Sanofi Pasteur
  • AIM Bio
  • Chengda Biotechnology
  • GlaxoSmithKline
  • Cansino Biologics
  • Sinovac
  • Lanzhou Institute of Biological Products
  • Royal (Wuxi) Bio-Pharmaceutical
  • Merck & Co.
  • Toyouvax
  • Walvax
  • Zhifei Biological

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Group A and C Meningococcal Polysaccharide Vaccine Market by Type
  3. 1.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Polysaccharide-protein Conjugate Vaccine
  5. 1.2.3 Polysaccharide Vaccine
  6. 1.3 Group A and C Meningococcal Polysaccharide Vaccine Market by Application
  7. 1.3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Centers for Disease Control and Prevention
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Group A and C Meningococcal Polysaccharide Vaccine Market Dynamics
  1. 2.1 Group A and C Meningococcal Polysaccharide Vaccine Industry Trends
  2. 2.2 Group A and C Meningococcal Polysaccharide Vaccine Industry Drivers
  3. 2.3 Group A and C Meningococcal Polysaccharide Vaccine Industry Opportunities and Challenges
  4. 2.4 Group A and C Meningococcal Polysaccharide Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region
  3. 3.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region
  9. 3.4.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Group A and C Meningococcal Polysaccharide Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Manufacturers
  6. 4.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Group A and C Meningococcal Polysaccharide Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Group A and C Meningococcal Polysaccharide Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Group A and C Meningococcal Polysaccharide Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Group A and C Meningococcal Polysaccharide Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Group A and C Meningococcal Polysaccharide Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Group A and C Meningococcal Polysaccharide Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Group A and C Meningococcal Polysaccharide Vaccine Tier 1, Tier 2, and Tier 3
5 Group A and C Meningococcal Polysaccharide Vaccine Market by Type
  1. 5.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type
  2. 5.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type
  6. 5.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2032) & (Units)
  8. 5.2.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Group A and C Meningococcal Polysaccharide Vaccine Price by Type
6 Group A and C Meningococcal Polysaccharide Vaccine Market by Application
  1. 6.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application
  2. 6.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application
  6. 6.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2032) & (Units)
  8. 6.2.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Group A and C Meningococcal Polysaccharide Vaccine Price by Application
7 Company Profiles
  1. 7.1 Pfizer
  2. 7.1.1 Pfizer Company Information
  3. 7.1.2 Pfizer Business Overview
  4. 7.1.3 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  6. 7.1.5 Pfizer Recent Developments
  7. 7.2 Sanofi Pasteur
  8. 7.2.1 Sanofi Pasteur Company Information
  9. 7.2.2 Sanofi Pasteur Business Overview
  10. 7.2.3 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  12. 7.2.5 Sanofi Pasteur Recent Developments
  13. 7.3 AIM Bio
  14. 7.3.1 AIM Bio Company Information
  15. 7.3.2 AIM Bio Business Overview
  16. 7.3.3 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  18. 7.3.5 AIM Bio Recent Developments
  19. 7.4 Chengda Biotechnology
  20. 7.4.1 Chengda Biotechnology Company Information
  21. 7.4.2 Chengda Biotechnology Business Overview
  22. 7.4.3 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  24. 7.4.5 Chengda Biotechnology Recent Developments
  25. 7.5 GlaxoSmithKline
  26. 7.5.1 GlaxoSmithKline Company Information
  27. 7.5.2 GlaxoSmithKline Business Overview
  28. 7.5.3 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  30. 7.5.5 GlaxoSmithKline Recent Developments
  31. 7.6 Cansino Biologics
  32. 7.6.1 Cansino Biologics Company Information
  33. 7.6.2 Cansino Biologics Business Overview
  34. 7.6.3 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  36. 7.6.5 Cansino Biologics Recent Developments
  37. 7.7 Sinovac
  38. 7.7.1 Sinovac Company Information
  39. 7.7.2 Sinovac Business Overview
  40. 7.7.3 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  42. 7.7.5 Sinovac Recent Developments
  43. 7.8 Lanzhou Institute of Biological Products
  44. 7.8.1 Lanzhou Institute of Biological Products Company Information
  45. 7.8.2 Lanzhou Institute of Biological Products Business Overview
  46. 7.8.3 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  48. 7.8.5 Lanzhou Institute of Biological Products Recent Developments
  49. 7.9 Royal (Wuxi) Bio-Pharmaceutical
  50. 7.9.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  51. 7.9.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
  52. 7.9.3 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  54. 7.9.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
  55. 7.10 Merck & Co.
  56. 7.10.1 Merck & Co. Company Information
  57. 7.10.2 Merck & Co. Business Overview
  58. 7.10.3 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  60. 7.10.5 Merck & Co. Recent Developments
  61. 7.11 Toyouvax
  62. 7.11.1 Toyouvax Company Information
  63. 7.11.2 Toyouvax Business Overview
  64. 7.11.3 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  66. 7.11.5 Toyouvax Recent Developments
  67. 7.12 Walvax
  68. 7.12.1 Walvax Company Information
  69. 7.12.2 Walvax Business Overview
  70. 7.12.3 Walvax Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Walvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  72. 7.12.5 Walvax Recent Developments
  73. 7.13 Zhifei Biological
  74. 7.13.1 Zhifei Biological Company Information
  75. 7.13.2 Zhifei Biological Business Overview
  76. 7.13.3 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  78. 7.13.5 Zhifei Biological Recent Developments
8 North America
  1. 8.1 North America Group A and C Meningococcal Polysaccharide Vaccine Market Size by Type
  2. 8.1.1 North America Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America Group A and C Meningococcal Polysaccharide Vaccine Price by Type (2021-2032)
  5. 8.2 North America Group A and C Meningococcal Polysaccharide Vaccine Market Size by Application
  6. 8.2.1 North America Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America Group A and C Meningococcal Polysaccharide Vaccine Price by Application (2021-2032)
  9. 8.3 North America Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country
  10. 8.3.1 North America Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Group A and C Meningococcal Polysaccharide Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Group A and C Meningococcal Polysaccharide Vaccine Market Size by Type
  2. 9.1.1 Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe Group A and C Meningococcal Polysaccharide Vaccine Price by Type (2021-2032)
  5. 9.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Market Size by Application
  6. 9.2.1 Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe Group A and C Meningococcal Polysaccharide Vaccine Price by Application (2021-2032)
  9. 9.3 Europe Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country
  10. 9.3.1 Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Group A and C Meningococcal Polysaccharide Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Group A and C Meningococcal Polysaccharide Vaccine Market Size by Type
  2. 10.1.1 China Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China Group A and C Meningococcal Polysaccharide Vaccine Price by Type (2021-2032)
  5. 10.2 China Group A and C Meningococcal Polysaccharide Vaccine Market Size by Application
  6. 10.2.1 China Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China Group A and C Meningococcal Polysaccharide Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Group A and C Meningococcal Polysaccharide Vaccine Market Size by Type
  2. 11.1.1 Asia Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia Group A and C Meningococcal Polysaccharide Vaccine Price by Type (2021-2032)
  5. 11.2 Asia Group A and C Meningococcal Polysaccharide Vaccine Market Size by Application
  6. 11.2.1 Asia Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia Group A and C Meningococcal Polysaccharide Vaccine Price by Application (2021-2032)
  9. 11.3 Asia Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country
  10. 11.3.1 Asia Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Group A and C Meningococcal Polysaccharide Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Group A and C Meningococcal Polysaccharide Vaccine Market Size by Type
  2. 12.1.1 SAMEA Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Group A and C Meningococcal Polysaccharide Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA Group A and C Meningococcal Polysaccharide Vaccine Market Size by Application
  6. 12.2.1 SAMEA Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Group A and C Meningococcal Polysaccharide Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country
  10. 12.3.1 SAMEA Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Group A and C Meningococcal Polysaccharide Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Group A and C Meningococcal Polysaccharide Vaccine Value Chain Analysis
  2. 13.1.1 Group A and C Meningococcal Polysaccharide Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Group A and C Meningococcal Polysaccharide Vaccine Production Mode & Process
  6. 13.2 Group A and C Meningococcal Polysaccharide Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Group A and C Meningococcal Polysaccharide Vaccine Distributors
  9. 13.2.3 Group A and C Meningococcal Polysaccharide Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst